Novartis and Novo Nordisk trials lower biomarkers but fail to cut heart events, prompting preventive cardiology rethink
The article discusses two recent Phase 3 trials that achieved their biological goals but did not improve clinical outcomes.
Novartis reported that pelacarsen in the Lp(a) HORIZON study successfully lowered lipoprotein(a) levels, yet it did not reduce heart attacks or strokes.
Novo Nordisk’s ZEUS trial showed that ziltivekimab reduced inflammatory markers, but it also failed to show a benefit in cardiovascular events.
The author concludes that these disappointments expose a gap between genetic or biomarker advances and real‑world therapeutic impact, calling for a reassessment of preventive cardiology approaches.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “Opinion: STAT+: A moment of reckoning for preventive cardiology and the precision medicine revolution”
read at STAT ↗
comments(0)
5-min edit window · permanent after that